SVA Sernova Corp

Sernova Corp (TSX VENTURE:SVA), today announced that Dr. Philip Toleikis, Ph.D.,
the company's Chief Executive Officer will present an update on the company's
business strategy and clinical study at the Biotech Showcase(TM) healthcare
conference in San Francisco, CA. This important conference brings together
global industry leaders, emerging companies and members of the investment
community. Sernova is currently conducting a Phase I/II clinical trial of its
Cell Pouch(TM) at the University of Alberta in patients with Type 1 diabetes who
are receiving an islet transplant with Dr. James Shapiro as principal
investigator.


Details of Sernova Corp's presentation are as follows:



Event:        Biotech Showcase(TM) 2014 Conference                          
Date:         January 14, 2014                                              
Time:         4:30 P.M. PST                                                 
Location:     Parc 55 Wyndham SF Union Sq. Hotel; 3(rd) Floor Track D Powell



"We are presenting Sernova's strategic approach and product development
advancements during the industry's largest conglomerate of annual healthcare
investor conferences and arguably the most important healthcare investment
symposia in the industry," remarked Dr. Philip Toleikis, President and CEO.  


"With Sernova anticipating the release of Phase I/II interim clinical efficacy
data in 2014, as well as advancements in our other programs and collaborations,
this is an excellent opportunity to highlight the company's progress and future
direction," added Dr. Toleikis.


About the Biotech Showcase(TM) (Innovation -Opportunity - Collaboration)

Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech Showcase
is an investor and partnering conference devoted to providing private and public
biotechnology and life sciences companies an opportunity to present to, and meet
with, investors and pharmaceutical executives during the course of one of the
industry's largest annual healthcare investor conferences. Now in its sixth
year, Biotech Showcase is expected to attract upwards of 1,500 attendees. 


About Sernova

Sernova Corp is a clinical stage regenerative medicine company developing
medical technologies for the treatment of chronic debilitating metabolic
diseases such as diabetes, blood disorders including haemophilia and other
diseases treated through replacement of proteins or hormones missing or in short
supply within the body. Sernova is developing the Cell Pouch(TM), an implantable
medical device for therapeutic cells (donor, xenogeneic or stem cells) which
then release proteins and/or hormones as required. The therapeutic cells are
protected from immune attack by Sernova's proprietary technology, Sertolin(TM). 


About the Cell Pouch(TM)

The Cell Pouch(TM) is a proprietary scalable biocompatible medical device,
contract manufactured (ISO13485) to meet international regulatory standards. It
is inserted under the skin, and forms an ideal environment, rich in microvessels
and tissue matrix for the placement and function of therapeutic cells. The Cell
Pouch(TM) is currently being evaluated in clinical trials at the University of
Alberta with Dr. James Shapiro as principal investigator in patients with Type 1
diabetes receiving an islet transplant. 


About Sertolin(TM)

Sertoli cells when co-localized with donor therapeutic cells release protective
factors that can provide a non-toxic, immune-protected environment that may
reduce or eliminate the need for daily anti-rejection drugs that currently must
be used by patients with transplanted tissues and organs. Sernova is currently
conducting preclinical studies to optimize sertoli cells and islets within the
Cell Pouch(TM) through a NRC-IRAP contribution agreement provided by the
Government of Canada. 


About Clinical Islet Transplantation Program

Please view www.islet.ca for more information on the Clinical Islet
Transplantation Program at the University of Alberta.


Forward Looking Information 

This release may contain forward-looking statements. Forward-looking statements
are statements that are not historical facts and are generally, but not always,
identified by the words "expects", "plans", "anticipates", "believes",
"intends", "estimates", "projects", "potential" and similar expressions, or that
events or conditions "will", "would", "may", "could" or "should" occur. Although
Sernova believes the expectations expressed in such forward-looking statements
are based on reasonable assumptions, such statements are not guarantees of
future performance and actual results may differ materially from those in
forward looking statements. Forward-looking statements are based on the beliefs,
estimates and opinions of Sernova's management on the date such statements were
made. Sernova expressly disclaims any intention or obligation to update or
revise any forward-looking statements whether as a result of new information,
future events or otherwise. 


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Sernova Corp
Philip Toleikis, Ph.D.
President and CEO
(604) 961-2939
info@sernova.com
www.sernova.com


Ray Matthews & Associates Inc.
Suite 601-128 West Cordova Street
Vancouver, BC V6B 0E6
604.818.7778
www.raymatthews.ca

Sernova (TSXV:SVA)
Historical Stock Chart
From Jan 2025 to Feb 2025

Sernova (TSXV:SVA)
Historical Stock Chart
From Feb 2024 to Feb 2025